London close: Stocks rise further ahead of BoE decision
8th May 2024 16:36
(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.
Read moreBerenberg hikes target price on Astrazeneca
7th May 2024 15:54
(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".
Read moreAstraZeneca reports positive results from blood cancer drug trial
2nd May 2024 07:45
(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.
Read moreAstraZeneca makes progress with two breast cancer treatments
29th Apr 2024 07:24
(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.
Read moreLondon close: Stocks finish mixed as US GDP growth slows
25th Apr 2024 15:14
(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.
Read moreAstraZeneca blows past analysts' estimates for Q1
25th Apr 2024 08:38
(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.
Read moreLondon close: Stocks finish lower as ECB stands pat
11th Apr 2024 15:56
(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.
Read moreAstraZeneca to hike 2024 dividend by 7%
11th Apr 2024 07:20
(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.
Read moreAstraZeneca's Enhurtu cancer gets US green light for adult patients
8th Apr 2024 07:02
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.
Read moreAstraZeneca announces positive lung cancer treatment trial results
5th Apr 2024 07:23
(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.
Read moreLondon close: Stocks turn red on return from Easter break
2nd Apr 2024 15:22
(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.
Read moreUS FDA gives green light for use of AstraZeneca's Voydeva
2nd Apr 2024 07:08
(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).
Read moreAstraZeneca gets FDA approval for Ultomiris treatment
25th Mar 2024 07:23
(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.
Read moreAstraZeneca to buy US-listed Fusion Phrama for $2bn
19th Mar 2024 07:05
(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.
Read moreAstraZeneca snaps up rare disease specialist Amolyt for $1.05bn
14th Mar 2024 07:16
(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.
Read more